Details
Stereochemistry | ACHIRAL |
Molecular Formula | C5H5NOS |
Molecular Weight | 127.164 |
Optical Activity | NONE |
Defined Stereocenters | 0 / 0 |
E/Z Centers | 0 |
Charge | 0 |
SHOW SMILES / InChI
SMILES
[O-][N+]1=CC=CC=C1S
InChI
InChIKey=FGVVTMRZYROCTH-UHFFFAOYSA-N
InChI=1S/C5H5NOS/c7-6-4-2-1-3-5(6)8/h1-4,8H
Molecular Formula | C5H5NOS |
Molecular Weight | 127.164 |
Charge | 0 |
Count |
|
Stereochemistry | ACHIRAL |
Additional Stereochemistry | No |
Defined Stereocenters | 0 / 0 |
E/Z Centers | 0 |
Optical Activity | NONE |
Pyrithione zinc is an antibacterial and antifungal agent developed by scientists in the 1930's. Since then it has been used to treat seborrheic dermatitis of the scalp and other skin conditions such as eczema, athlete's foot, and vitiligo, as well as psoriasis. Because of its antifungal properties, it is commonly found in dandruff shampoo. Products containing pyrithione zinc are available today with and without prescription, and it is the main ingredient in many over-the-counter creams, lotions, soaps, and shampoos. It also has antibacterial properties and is effective against many pathogens from the Streptococcus and Staphylococcus genera. Pyrithione zinc`s other medical applications include treatments of psoriasis, eczema, ringworm, fungus, athletes foot, dry skin, atopic dermatitis, tinea, and vitiligo. Its antifungal effect is thought to derive from its ability to disrupt membrane transport by blocking the proton pump that energizes the transport mechanism.
Approval Year
Targets
Primary Target | Pharmacology | Condition | Potency |
---|---|---|---|
Target ID: CHEMBL5705 Sources: https://www.ncbi.nlm.nih.gov/pubmed/26940742 |
0.98 µM [IC50] | ||
Target ID: GO:0006927 Sources: https://www.ncbi.nlm.nih.gov/pubmed/22105358 |
|||
Target ID: CHEMBL4261 Sources: https://www.ncbi.nlm.nih.gov/pubmed/20473380 |
Conditions
Condition | Modality | Targets | Highest Phase | Product |
---|---|---|---|---|
Curative | Pyrithione zinc shampoo Approved UsePyrithione zinc shampoo is used for:
Treating and preventing itching, flaking, and scaling of the scalp caused by dandruff or seborrhea (oily, crusting, or scaling skin).
Pyrithione zinc shampoo is an antiseborrheic. It works by slowing the production of skin cells, which helps to reduce flakiness. Launch Date1986 |
|||
Primary | Unknown Approved UseUnknown |
Cmax
Value | Dose | Co-administered | Analyte | Population |
---|---|---|---|---|
0.2 μg/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/730082/ |
0.5 mg/kg single, oral dose: 0.5 mg/kg route of administration: Oral experiment type: SINGLE co-administered: |
PYRITHIONE plasma | Rattus norvegicus population: HEALTHY age: ADULT sex: MALE food status: FASTED |
AUC
Value | Dose | Co-administered | Analyte | Population |
---|---|---|---|---|
27.01 μg × h/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/730082/ |
0.5 mg/kg single, oral dose: 0.5 mg/kg route of administration: Oral experiment type: SINGLE co-administered: |
PYRITHIONE plasma | Rattus norvegicus population: HEALTHY age: ADULT sex: MALE food status: FASTED |
T1/2
Value | Dose | Co-administered | Analyte | Population |
---|---|---|---|---|
115 h EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/730082/ |
0.5 mg/kg single, oral dose: 0.5 mg/kg route of administration: Oral experiment type: SINGLE co-administered: |
PYRITHIONE plasma | Rattus norvegicus population: HEALTHY age: ADULT sex: MALE food status: FASTED |
Doses
Dose | Population | Adverse events |
---|---|---|
1 % 2 times / week multiple, topical Recommended Dose: 1 %, 2 times / week Route: topical Route: multiple Dose: 1 %, 2 times / week Sources: Page: p.436, 438 |
unhealthy, 17–64 n = 160 Health Status: unhealthy Condition: Severe dandruff |Seborrheic dermatitis Age Group: 17–64 Sex: M+F Population Size: 160 Sources: Page: p.436, 438 |
Disc. AE: Erythema... AEs leading to discontinuation/dose reduction: Erythema (1.25%) Sources: Page: p.436, 438 |
AEs
AE | Significance | Dose | Population |
---|---|---|---|
Erythema | 1.25% Disc. AE |
1 % 2 times / week multiple, topical Recommended Dose: 1 %, 2 times / week Route: topical Route: multiple Dose: 1 %, 2 times / week Sources: Page: p.436, 438 |
unhealthy, 17–64 n = 160 Health Status: unhealthy Condition: Severe dandruff |Seborrheic dermatitis Age Group: 17–64 Sex: M+F Population Size: 160 Sources: Page: p.436, 438 |
PubMed
Title | Date | PubMed |
---|---|---|
Flow injection analysis of zinc pyrithione in hair care products on a cobalt phthalocyanine modified screen-printed carbon electrode. | 2004 Apr 19 |
|
Endogenous zinc in neurological diseases. | 2005 Oct |
|
Overexpression of DSCR1 blocks zinc-induced neuronal cell death through the formation of nuclear aggregates. | 2007 Aug |
|
Opposing effects of ERK and p38 MAP kinases on HeLa cell apoptosis induced by dipyrithione. | 2007 Feb 28 |
|
Chemical genetics suggests a critical role for lysyl oxidase in zebrafish notochord morphogenesis. | 2007 Jan |
|
Protective role of intracellular zinc in myocardial ischemia/reperfusion is associated with preservation of protein kinase C isoforms. | 2007 May |
|
Role of zinc influx via AMPA/kainate receptor activation in metabotropic glutamate receptor-mediated calcium release. | 2007 May 1 |
|
Time-dependent X-ray absorption spectroscopic (XAS) study on the transformation of zinc basic salt into bis(N-oxopyridine-2-thionato) zinc (II). | 2007 Nov |
|
Toxicity of four antifouling biocides and their mixtures on the brine shrimp Artemia salina. | 2007 Nov 15 |
|
Preliminary evaluation of antimicrobial activity of some chemicals on in vitro apple shoots infected by 'Candidatus Phytoplasma mali'. | 2008 |
|
NADPH-dependent coenzyme Q reductase is the main enzyme responsible for the reduction of non-mitochondrial CoQ in cells. | 2008 |
|
Synergistic toxic effects of zinc pyrithione and copper to three marine species: Implications on setting appropriate water quality criteria. | 2008 |
|
2-(Benzyl-sulfan-yl)pyridine N-oxide. | 2008 Apr 26 |
|
In vitro-refolding of a single-chain Fv fragment in the presence of heteroaromatic thiols. | 2008 Apr 30 |
|
Comparative effects of sodium pyrithione evoked intracellular calcium elevation in rodent and primate ventral horn motor neurons. | 2008 Feb 1 |
|
Poly[ethano-lbis(μ(3)-2-thio-xo-1,2-dihydro-pyridin-1-olato)dilithium(I)]. | 2008 Feb 8 |
|
Thioperoxy derivative generated by UV-induced transformation of N-hydroxypyridine-2(1H)-thione isolated in low-temperature matrixes. | 2008 Jan 17 |
|
2,2'-[2,3,5,6-Tetra-methyl-p-phenyl-ene-bis(methyl-enethio)]bis-(pyridine N-oxide). | 2008 Jan 9 |
|
Synthesis and anticancer properties of water-soluble zinc ionophores. | 2008 Jul 1 |
|
Aryl-bridged 1-hydroxypyridin-2-one: sensitizer ligands for Eu(III). | 2008 Jul 21 |
|
Potent in vitro anti-Trypanosoma cruzi activity of pyridine-2-thiol N-oxide metal complexes having an inhibitory effect on parasite-specific fumarate reductase. | 2008 Jun |
|
Insights into Zn2+ homeostasis in neurons from experimental and modeling studies. | 2008 Mar |
|
Exogenous zinc protects cardiac cells from reperfusion injury by targeting mitochondrial permeability transition pore through inactivation of glycogen synthase kinase-3beta. | 2008 Sep |
|
2-(Mesitylmethylsulfanyl)pyridine N-oxide monohydrate. | 2008 Sep 17 |
|
2-(2,3,5,6-Tetra-methyl-benzyl-sulfan-yl)pyridine N-oxide. | 2008 Sep 20 |
|
Trace metals in antifouling paint particles and their heterogeneous contamination of coastal sediments. | 2009 Apr |
|
Molecular mechanism underlying Akt activation in zinc-induced cardioprotection. | 2009 Aug |
|
Rising zinc: a significant cause of ischemic neuronal death in the CA1 region of rat hippocampus. | 2009 Aug |
|
Leaching of hydrophobic Cu and Zn from discarded marine antifouling paint residues: evidence for transchelation of metal pyrithiones. | 2009 Dec |
|
Pannexin-1-dependent caspase-1 activation and secretion of IL-1beta is regulated by zinc. | 2009 Feb |
|
Electrospray ionization mass spectrometric observation of ligand exchange of zinc pyrithione with amino acids. | 2009 Jul |
|
Biofouling growth in cold estuarine waters and evaluation of some chitosan and copper anti-fouling paints. | 2009 Jul 14 |
|
Clioquinol and pyrithione activate TRPA1 by increasing intracellular Zn2+. | 2009 May 19 |
|
Metal ionophores - an emerging class of anticancer drugs. | 2009 Nov |
|
Tracing of intracellular zinc(II) fluorescence flux to monitor cell apoptosis by using FluoZin-3AM. | 2009 Oct |
|
Synthesis and characterization of a pyridine-2-thiol N-oxide gold(I) complex with potent antiproliferative effect against Trypanosoma cruzi and Leishmania sp. insight into its mechanism of action. | 2009 Oct |
|
Pyrithione and 8-hydroxyquinolines transport lead across erythrocyte membranes. | 2009 Sep |
|
Insulin storage and glucose homeostasis in mice null for the granule zinc transporter ZnT8 and studies of the type 2 diabetes-associated variants. | 2009 Sep |
|
Dandruff: the most commercially exploited skin disease. | 2010 Apr-Jun |
|
Activation of the orphan receptor tyrosine kinase ALK by zinc. | 2010 Aug 6 |
|
The roles of iPLA2, TRPM8 and TRPA1 in chemically induced cold hypersensitivity. | 2010 Jan 21 |
|
An integrated imaging approach to the study of oxidative stress generation by mitochondrial dysfunction in living cells. | 2010 Jul |
|
DNA microarray analysis suggests that zinc pyrithione causes iron starvation to the yeast Saccharomyces cerevisiae. | 2010 May |
|
Zinc signals promote IL-2-dependent proliferation of T cells. | 2010 May |
|
Cellular zinc homeostasis is a regulator in monocyte differentiation of HL-60 cells by 1 alpha,25-dihydroxyvitamin D3. | 2010 May |
|
K+ channel openers restore verapamil-inhibited lung fluid resolution and transepithelial ion transport. | 2010 May 27 |
|
Novel antifouling agent zinc pyrithione: determination, acute toxicity, and bioaccumulation in marine mussels (Mytilus galloprovincialis). | 2010 Nov |
|
Zinc in innate and adaptive tumor immunity. | 2010 Nov 18 |
|
Zn(2+) inhibits coronavirus and arterivirus RNA polymerase activity in vitro and zinc ionophores block the replication of these viruses in cell culture. | 2010 Nov 4 |
|
UVB radiation induces an increase in intracellular zinc in human epidermal keratinocytes. | 2010 Oct |
Sample Use Guides
Shake well before each use.
Wet hair thoroughly. Apply pyrithione zinc shampoo and work into a lather. Rinse thoroughly and repeat.
For best results, use pyrithione zinc shampoo at least 2 times per week or as directed by your doctor. Do not use more often than once daily.
Route of Administration:
Topical
In Vitro Use Guide
Sources: https://www.ncbi.nlm.nih.gov/pubmed/3882533
Pyrithione zinc had a reversible inhibitory effect on the growth of BHK 21 cells at 0.1 ug/ml, but had a rapid, irreversible inhibitory effect at 1 ug/ml associated with cell rounding and detachment.
Substance Class |
Chemical
Created
by
admin
on
Edited
Fri Dec 15 16:34:07 GMT 2023
by
admin
on
Fri Dec 15 16:34:07 GMT 2023
|
Record UNII |
6GK82EC25D
|
Record Status |
Validated (UNII)
|
Record Version |
|
-
Download
Name | Type | Language | ||
---|---|---|---|---|
|
Common Name | English | ||
|
Code | English | ||
|
Common Name | English | ||
|
Systematic Name | English | ||
|
Common Name | English | ||
|
Systematic Name | English | ||
|
Systematic Name | English | ||
|
Common Name | English |
Classification Tree | Code System | Code | ||
---|---|---|---|---|
|
NCI_THESAURUS |
C29708
Created by
admin on Fri Dec 15 16:34:07 GMT 2023 , Edited by admin on Fri Dec 15 16:34:07 GMT 2023
|
||
|
NCI_THESAURUS |
C514
Created by
admin on Fri Dec 15 16:34:07 GMT 2023 , Edited by admin on Fri Dec 15 16:34:07 GMT 2023
|
Code System | Code | Type | Description | ||
---|---|---|---|---|---|
|
DB06815
Created by
admin on Fri Dec 15 16:34:07 GMT 2023 , Edited by admin on Fri Dec 15 16:34:07 GMT 2023
|
PRIMARY | |||
|
179790
Created by
admin on Fri Dec 15 16:34:07 GMT 2023 , Edited by admin on Fri Dec 15 16:34:07 GMT 2023
|
PRIMARY | |||
|
C61916
Created by
admin on Fri Dec 15 16:34:07 GMT 2023 , Edited by admin on Fri Dec 15 16:34:07 GMT 2023
|
PRIMARY | |||
|
35100
Created by
admin on Fri Dec 15 16:34:07 GMT 2023 , Edited by admin on Fri Dec 15 16:34:07 GMT 2023
|
PRIMARY | RxNorm | ||
|
214-328-9
Created by
admin on Fri Dec 15 16:34:07 GMT 2023 , Edited by admin on Fri Dec 15 16:34:07 GMT 2023
|
ALTERNATIVE | |||
|
DTXSID4048010
Created by
admin on Fri Dec 15 16:34:07 GMT 2023 , Edited by admin on Fri Dec 15 16:34:07 GMT 2023
|
PRIMARY | |||
|
Pyrithione
Created by
admin on Fri Dec 15 16:34:07 GMT 2023 , Edited by admin on Fri Dec 15 16:34:07 GMT 2023
|
PRIMARY | |||
|
214-329-4
Created by
admin on Fri Dec 15 16:34:07 GMT 2023 , Edited by admin on Fri Dec 15 16:34:07 GMT 2023
|
PRIMARY | |||
|
6GK82EC25D
Created by
admin on Fri Dec 15 16:34:07 GMT 2023 , Edited by admin on Fri Dec 15 16:34:07 GMT 2023
|
PRIMARY | |||
|
SUB126800
Created by
admin on Fri Dec 15 16:34:07 GMT 2023 , Edited by admin on Fri Dec 15 16:34:07 GMT 2023
|
PRIMARY | |||
|
1121-31-9
Created by
admin on Fri Dec 15 16:34:07 GMT 2023 , Edited by admin on Fri Dec 15 16:34:07 GMT 2023
|
PRIMARY | |||
|
C008704
Created by
admin on Fri Dec 15 16:34:07 GMT 2023 , Edited by admin on Fri Dec 15 16:34:07 GMT 2023
|
PRIMARY | |||
|
6GK82EC25D
Created by
admin on Fri Dec 15 16:34:07 GMT 2023 , Edited by admin on Fri Dec 15 16:34:07 GMT 2023
|
PRIMARY | |||
|
36578
Created by
admin on Fri Dec 15 16:34:07 GMT 2023 , Edited by admin on Fri Dec 15 16:34:07 GMT 2023
|
PRIMARY | |||
|
m9377
Created by
admin on Fri Dec 15 16:34:07 GMT 2023 , Edited by admin on Fri Dec 15 16:34:07 GMT 2023
|
PRIMARY | Merck Index | ||
|
100000153000
Created by
admin on Fri Dec 15 16:34:07 GMT 2023 , Edited by admin on Fri Dec 15 16:34:07 GMT 2023
|
PRIMARY | |||
|
1121-30-8
Created by
admin on Fri Dec 15 16:34:07 GMT 2023 , Edited by admin on Fri Dec 15 16:34:07 GMT 2023
|
ALTERNATIVE | |||
|
3508
Created by
admin on Fri Dec 15 16:34:07 GMT 2023 , Edited by admin on Fri Dec 15 16:34:07 GMT 2023
|
PRIMARY |
Related Record | Type | Details | ||
---|---|---|---|---|
|
SALT/SOLVATE -> PARENT | |||
|
SALT/SOLVATE -> PARENT | |||
|
SALT/SOLVATE -> PARENT | |||
|
SALT/SOLVATE -> PARENT |
Related Record | Type | Details | ||
---|---|---|---|---|
|
ACTIVE MOIETY |